fancg

fancg

Overview

The FANCG gene (Fanconi Anemia Group G), also known as XRCC9, encodes a critical component of the Fanconi anemia (FA) DNA repair pathway. FANCG is a core member of the multi-subunit FA core complex, which functions as an E3 ubiquitin ligase necessary for the monoubiquitination of FANCD2 and FANCI— the central activating events in the repair of DNA interstrand crosslinks (ICLs) [liu2001]. The protein is characterized by multiple tetratricopeptide repeat (TPR) domains that mediate protein-protein interactions essential for assembly and function of the FA core complex.

FANCG mutations cause Fanconi anemia complementation group G (FA-G), characterized by congenital abnormalities, bone marrow failure, and predisposition to both hematological and solid malignancies. Given the pathway's fundamental role in maintaining genomic stability, FANCG has attracted significant attention for understanding DNA repair mechanisms and cancer predisposition syndromes [niedernhofer2007].

Beyond its well-established role in ICL repair, emerging evidence suggests that FANCG and other FA pathway proteins may contribute to neuronal survival in neurodegenerative diseases. The FA pathway's intersection with DNA repair, transcriptional regulation, and cellular stress response positions it as a potentially important player in age-related neurodegeneration [niraj2017].

fancg

Overview

The FANCG gene (Fanconi Anemia Group G), also known as XRCC9, encodes a critical component of the Fanconi anemia (FA) DNA repair pathway. FANCG is a core member of the multi-subunit FA core complex, which functions as an E3 ubiquitin ligase necessary for the monoubiquitination of FANCD2 and FANCI— the central activating events in the repair of DNA interstrand crosslinks (ICLs) [liu2001]. The protein is characterized by multiple tetratricopeptide repeat (TPR) domains that mediate protein-protein interactions essential for assembly and function of the FA core complex.

FANCG mutations cause Fanconi anemia complementation group G (FA-G), characterized by congenital abnormalities, bone marrow failure, and predisposition to both hematological and solid malignancies. Given the pathway's fundamental role in maintaining genomic stability, FANCG has attracted significant attention for understanding DNA repair mechanisms and cancer predisposition syndromes [niedernhofer2007].

Beyond its well-established role in ICL repair, emerging evidence suggests that FANCG and other FA pathway proteins may contribute to neuronal survival in neurodegenerative diseases. The FA pathway's intersection with DNA repair, transcriptional regulation, and cellular stress response positions it as a potentially important player in age-related neurodegeneration [niraj2017].
<div class="infobox infobox-gene">
<table>
<tr><th>Gene Symbol</th><td>FANCG</td></tr>
<tr><th>Gene Name</th><td>Fanconi Anemia Group G (XRCC9)</td></tr>
<tr><th>Chromosome</th><td>9p13.3</td></tr>
<tr><th>NCBI Gene ID</th><td><a href="https://www.ncbi.nlm.nih.gov/gene/2188" target="_blank">2188</a></td></tr>
<tr><th>OMIM</th><td><a href="https://www.omim.org/entry/602956" target="_blank">602956</a></td></tr>
<tr><th>UniProt</th><td><a href="https://www.uniprot.org/uniprot/O43272" target="_blank">O43272</a></td></tr>
<tr><th>Ensembl ID</th><td><a href="https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000221838" target="_blank">ENSG00000221838</td></tr>
<tr><th>Protein Length</th><td>622 amino acids</td></tr>
<tr><th>Associated Diseases</th><td>Fanconi Anemia, Alzheimer's Disease, Parkinson's Disease</td></tr>
</table>
</div>

Gene Structure and Protein Architecture

Genomic Organization

The FANCG gene is located on chromosome 9p13.3 and spans approximately 6.2 kb of genomic DNA consisting of 14 exons. The gene encodes a protein of 622 amino acids with a molecular weight of approximately 68 kDa. The gene promoter contains canonical TATA and CAAT box elements as well as binding sites for multiple transcription factors including Sp1 and p53, which regulate constitutive and stress-inducible expression.

Tetratricopeptide Repeat Domains

The defining structural feature of FANCG is the presence of multiple tetratricopeptide repeat (TPR) domains throughout the protein [kim2018]. TPR domains are 34-amino acid repeating motifs that form amphipathic helices capable of mediating protein-protein interactions:

The TPR domains create a scaffold that organizes the FA core complex and facilitates proper positioning of catalytic components. Structural studies suggest that FANCG acts as a central hub connecting multiple FA core subunits.

Evolutionary Conservation

FANCG shows conservation across vertebrates:

• Human-Mouse: 82% identical at the amino acid level
• Human-Zebrafish: 65% identical
• Drosophila: Partial ortholog with 40% identity
• Yeast: No clear ortholog

Biological Functions

FA Core Complex Assembly

FANCG is an essential component of the FA core complex, a multi-subunit E3 ubiquitin ligase comprising FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, and FANCM [reuter2018]. The complex assembles in response to DNA damage and is required for activation of the downstream FA pathway:

Protein-Protein Interactions

FANCG interacts with multiple proteins essential for FA pathway function:

| Partner Protein | Interaction Domain | Functional Consequence |
|-----------------|-------------------|----------------------|
| FANCA | TPR1 (100-150) | Core complex stability |
| FANCF | TPR2 (200-280) | Heterodimer formation |
| FANCL | TPR3 (350-430) | E3 ligase recruitment |
| FANCD2 | C-terminal | Substrate presentation |
| XRCC1 | C-terminal | Backup ICL repair |

Role in ICL Repair

The FA core complex, including FANCG, is required for ICL repair through the following sequence [tani2019]:

FANCG contributes to this pathway by stabilizing the FA core complex and ensuring proper catalytic function. FANCG-deficient cells show severely impaired FANCD2 monoubiquitination and ICL repair capacity.

Disease Associations

Fanconi Anemia

Biallelic FANCG mutations cause Fanconi anemia complementation group G (FA-G), accounting for approximately 9% of all FA cases [castella2015]:

• Congenital abnormalities: Radial ray defects, growth retardation, microcephaly
• Bone marrow failure: Progressive pancytopenia
• Cancer predisposition: Acute myeloid leukemia, solid tumors
• Cellular phenotype: Extreme sensitivity to DNA crosslinking agents

Neurodegeneration

While not traditionally classified as a neurodegeneration gene, FANCG may contribute to neuronal survival through several mechanisms [niraj2017]:

• DNA repair capacity: Post-mitotic neurons accumulate DNA damage over time
• Transcriptional regulation: FA pathway proteins interact with transcriptional complexes
• Cellular stress response: FA pathway activation in response to oxidative stress
• Aging: Age-related decline in DNA repair capacity may contribute to neurodegeneration

Expression Patterns

FANCG is expressed ubiquitously with highest levels in:

• Bone marrow: Hematopoietic stem cells require robust DNA repair
• Testis: High proliferative activity in spermatogenesis
• Ovary: Meiotic cells require ICL repair
• Brain: Moderate expression in neurons and glia

Signaling Pathways

DNA Damage Response

Intersections with Other Pathways

FANCG intersects with several other DNA repair and signaling pathways:

• Nucleotide Excision Repair (NER): Initial ICL unhooking requires NER factors
• Homologous Recombination (HR): RAD51-mediated strand invasion for error-free repair
• Translesion Synthesis (TLS): Polymerase eta and kappa bypass the unhooked lesion
• Checkpoint Signaling: ATM/ATR kinases activate FA pathway in response to damage

Therapeutic Implications

Treatment Strategies

Current therapeutic approaches for FA include:

• Androgen therapy: Androgens can partially improve bone marrow function
• HSCT: Hematopoietic stem cell transplantation remains the only curative option
• Gene therapy: Experimental approaches to deliver wild-type FANCG

Cancer Predisposition

The FA pathway's role in genomic stability has significant implications for cancer:

• Synthetic lethality: PARP inhibitors show enhanced toxicity in FA-deficient cells
• Chemotherapy: FA pathway defects sensitize to DNA crosslinking agents
• Screening: FANCG mutation carriers benefit from cancer surveillance

Research Tools

• Animal models: Fancc and Fancg knockout mice are available
• Cell lines: FANCG-deficient patient cell lines for research
• Structural biology: Crystal structures of TPR domains inform mechanism

See Also

• [FANCG Protein](/proteins/fancg-protein) - The FANCG protein
• [FANCD2](/genes/fancd2) - Fanconi Anemia Group D2
• [FANCA](/genes/fanca) - Fanconi Anemia Group A
• [FANCF](/genes/fancf) - Fanconi Anemia Group F
• [Fanconi Anemia Pathway](/mechanisms/fanconi-anemia-pathway)
• [DNA Interstrand Crosslink Repair](/mechanisms/dna-interstrand-crosslink-repair)

External Links

• [NCBI Gene: FANCG](https://www.ncbi.nlm.nih.gov/gene/2188)
• [OMIM: FANCG](https://www.omim.org/entry/602956)
• [Ensembl: FANCG](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000221838)
• [UniProt: FANCG](https://www.uniprot.org/uniprot/O43272)
• [Fanconi Anemia Research Fund](https://www.fanconi.org/)

References